Artículos del autor

solaci

PHARMACOLOGY

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful...
solaci -
Institutional News

Watch again the the 10th ProEducar Educational Meeting- Structural Intervention II

Watch again the "10th ProEducar Educational Meeting - Learning with Experts" on Structural Intervention on our Youtube...
solaci -
Chronic Ischemic cardiopathy

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI...
solaci -
Other

AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not...
solaci -
Institutional News

SOLACI Webinar – New Frontiers in the Cath Lab

solaci -
Other

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and...
solaci -
Institutional News

Webinar Women As One@SOLACI-CACI: Liliana Grinfeld Symposium

Register HERE
solaci -
Antithrombotic Anticoagulants

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve

Rivaroxaban seems to be a reasonable alternative to warfarin in patients with atrial fibrillation and bioprosthetic mitral...
solaci -